Palatin Technologies

278 articles with Palatin Technologies

• Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis

  6/6/2019

  PL-8177 is a Melanocortin Receptor 1 Agonist

• Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

  5/9/2019

  Palatin Technologies, Inc. announced results for its third quarter ended March 31, 2019.

• Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

  5/3/2019

  Palatin Technologies, Inc. will announce its third quarter, fiscal year 2019 operating results on Thursday, May 9, 2019 before the open of the U.S. financial markets.

• Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

  4/4/2019

  Study Met All Primary and Secondary Endpoints

• Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update

  2/12/2019

  Palatin Technologies, Inc. announced results for its second quarter ended December 31, 2018.

• Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019

  2/6/2019

  Palatin Technologies, Inc. will announce its second quarter fiscal year 2019 operating results on Tuesday, February 12, 2019 before the open of the U.S. financial markets.

• Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update

  11/13/2018

  Teleconference and Webcast to be held on November 13, 2018

• Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist

  11/8/2018

  Oral Formulation Clinical Data Currently Anticipated by Year End

• Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018

  11/7/2018

  Palatin Technologies, Inc. will announce its first quarter fiscal year 2019 operating results on Tuesday, November 13, 2018 before the open of the U.S. financial markets.

• Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

  9/13/2018

  Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems for the treatment of diseases with significant unmet medical need and commercial potential

• Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

  9/7/2018

  Palatin Technologies, Inc. will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018 before the open of the U.S. financial markets.

• Palatin Technologies Added to Russell 3000® Index

  6/25/2018

  Palatin Technologies, Inc. announced that it has been added to the Russell 3000® Index as part of the annual Russell U.S. Index reconstitution.

• Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

  6/4/2018

  PDUFA Target Action Date March 23, 2019 Triggers Milestone Payment to Palatin of $20 Million

• Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

  5/15/2018

  Palatin is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential

• Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

  5/10/2018

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets.

• Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

  5/9/2018

  PL-8177 Evaluated in Animal Models of Inflammatory Bowel Disease and Autoimmune Uveitis

• Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases

  4/3/2018

  PL-8177 is Palatin's lead clinical development candidate for ulcerative colitis and other inflammatory bowel diseases.

• Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

  3/26/2018

  NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints

• Palatin Technologies Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018

  2/12/2018

  Palatin Technologies today announced results for its second quarter ended December 31, 2017.

• Palatin Technologies to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018

  2/8/2018

  Palatin Technologies will announce its second quarter, fiscal year 2018 operating results on Monday, February 12, 2018 before the open of the U.S. financial markets.